

A New and Convenient Synthesis of 1 α ,25-Dihydroxyvitamin D₂ and Its 24*R*-Epimer

Masahiro TSUJI,* Shinji YOKOYAMA, and Yoji TACHIBANA

Research Center, Nisshin Flour Milling, Co., Ltd., Ooimachi, Iruma-gun, Saitama 354

(Received April 8, 1989)

1 α , 25-Dihydroxyvitamin D₂ (**1a**) was synthesized by irradiation and subsequent thermal isomerization of (22*E*)-5,7,22-ergostatriene-1 α ,3 β ,25-triol (**16a**). The triol **16a** was obtained via 22-oxo-5 α ,8 α -(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)-23,24-dinor-6-chole-1 α ,3 β -diyl diacetate (**12**) starting from (22*E*)-5,7,22-ergostatriene-1 α ,3 β -diyl diacetate (**10**), a precursor of 1 α -hydroxyvitamin D₂. Introduction of the new side chain with the desired stereochemistry was carried out selectively by the reductive elimination of the β -hydroxy sulfone derived from the C-22 aldehyde (**12**) and an optically active sulfone, prepared via (S)-2,3-dimethyl-1,3-butanediol from methyl (S)-3-hydroxy-2-methylpropionate. Similarly a C-24 epimer of **1a** was synthesized.


Although the metabolism of vitamin D₂ (ercalcinol) has not been extensively investigated as in the case of vitamin D₃ (calcitriol), it has been shown that vitamin D₂ is hydroxylated at C-25 position in the liver to 25-hydroxyvitamin D₂ (ercalcidiol) and subsequently at the C-1 α position in the kidney to 1 α ,25-dihydroxyvitamin D₂ (ercalcitriol) (**1a**), a most potent metabolite.^{1,2)} Because it has been reported that 1 α -hydroxyvitamin D₂ ((1*S*)-hydroxyercalcinol)^{3,4)} is less toxic than the corresponding 1 α -hydroxyvitamin D₃ ((1*S*)-hydroxycalcitriol), in spite of the almost equal potency of vitamin D activity,^{5–7)} much attention has been paid to the 1 α -hydroxylated vitamin D₂. However, 1 α ,25-dihydroxyvitamin D₂ (**1a**), an “active form” of vitamin D₂, seems to be more potent than 1 α -hydroxyvitamin D₂ for vitamin D activity, because **1a** is thought to elicit its physiological activity after being hydroxylated at C-25 position as described above. These observations prompted us to investigate the synthesis of **1a** and its 24*R*-epimer (**1b**).

DeLuca et al. reported the synthesis of **1a** and/or **1b**^{8,9)} by the selective hydroxylation at C-1 α position of cyclovitamin D derivatives. However, this method

tamin D derivatives are easily and selectively converted to the corresponding 1 α -hydroxylated vitamin D derivatives.


Previously, we reported the convenient synthesis of (22*E*)-5,7,22-ergostatriene-1 α ,3 β -diyl diacetate (**10**),¹¹⁾ a precursor of 1 α -hydroxyvitamin D₂. To our best knowledge, no one has used this **10** in the synthesis of **1a** and **1b**. The C-22 aldehyde (**12**), available readily from **10**, seemed to be a good key-intermediate for the preparation of **1a** and **1b**. In the present paper we wish to describe a new and convenient synthesis of **1a** and **1b** using **10** as the starting material.

The side-chain fragments, namely optically active sulfones **9a**¹²⁾ for **1a** and **9b**⁹⁾ for **1b**, were synthesized respectively starting from methyl (S)- and (R)-3-hydroxy-2-methylpropionate (**2a** and **2b**) as follows (Scheme 1). Although it would be possible to convert **2a** directly to the diol (**5a**) by the Grignard reaction, this method gave a poor yield of **5a** due to its solubility in water. Thus, the hydroxyl group of **2a** was protected as a tetrahydropyranyl (THP) ether¹³⁾ to give **3a**.



gave 1 β -hydroxylated and transvitamin D derivatives as by-products, which were difficult to separate from the 1 α -hydroxylated compound. Although Baggiolini et al. reported the synthesis of **1a**,¹⁰⁾ their procedure is complicated.

It is advantageous to use the steroidal block as an intermediate for the preparation of 1 α -hydroxylated vitamin D derivatives, because 1 α -hydroxylated provi-



Scheme 1. a) DHP, *p*-TsOH; b) MeMgI/Et₂O; c) *p*-TsOH/MeOH; d) *p*-TsCl, Py; e) PhSH, *t*-BuOK/DMF; f) Na₂WO₄-H₂O₂; g) DHP, PPTS.


The Grignard reaction of **3a** using methylmagnesium iodide in ether afforded **4a**, which was subsequently subjected to deprotection of the THP group to provide the diol (**5a**) after distillation in 84% yield from **2a**. Tosylation of the primary hydroxyl group of **5a** in the usual manner afforded the tosylate (**6a**), which was reacted with benzenethiol in the presence of potassium *t*-butoxide in DMF to give the phenyl sulfide (**7a**). Oxidation of **7a** with Na₂WO₄-H₂O₂ yielded the crystalline hydroxy sulfone (**8a**) in 92% yield. Conventional protection of the hydroxyl group of **8a** as a THP ether gave **9a** in 92% yield. Similarly, **2b** was converted to the corresponding sulfone (**9b**) via the hydroxy sulfone (**8b**).

The next task was to construct the (22*E*)-olefin moiety leading to **1a** and **1b** (Scheme 2). The 5,7-diene of (22*E*)-5,7,22-ergostatriene-1 α ,3 β -diyl diacetate (**10**), our starting material, was protected as a Diels-Alder adduct with 4-phenyl-3*H*-1,2,4-triazole-3,5(4*H*)-dione (PTAD)¹⁴ to give **11** in 87% yield. Selective cleavage of the side-chain double bond of **11** was achieved by ozonolysis at -65 °C in 1% pyridine-CH₂Cl₂ solution and successive reductive workup of the resulting ozonide with dimethyl sulfide^{14,15} to give the C-22 aldehyde (**12**) after recrystallization in 49% yield. The ¹H NMR spectrum of **12** exhibited only a

doublet at δ 9.55 for the aldehyde proton (22-H), while the ¹H NMR spectrum of C(20) epimeric mixture, obtained by treatment of **12** with alumina (grade II—III) in CHCl₃,¹⁴ showed a pair of doublets at δ 9.55 and 9.48. This indicates that the aldehyde obtained (**12**) was a single isomer.

Addition of the aldehyde (**12**) to the carbanion generated from the sulfone (**9a**) by butyllithium in THF^{16–18} gave the β -hydroxy sulfone (**13a**), which was used in the next step without further purification. Reductive elimination of the β -hydroxy sulfone (**13a**) with sodium amalgam in buffered MeOH (Na₂HPO₄)^{16–18} afforded the olefinic product (**14a**) in 32% yield from **12**. This olefination reaction is known to give predominantly or exclusively an (*E*)-olefin.^{16–19} Removal of the THP group of **14a** by pyridinium *p*-toluenesulfonate (PPTS) in EtOH afforded the triol (**15a**), which was treated with LiAlH₄ in refluxing THF for removal of the triazoledione protective group¹⁴ to give (22*E*)-5,7,22-ergostatriene-1 α ,3 β ,25-triol (**16a**) in 54% yield from **14a**.

Irradiation^{3,4} of the 5,7-diene-1 α ,3 β ,25-triol (**16a**) with a high-pressure mercury lamp using aq. 1.5% KNO₃ solution as a filter gave the previtamin D (**17a**). Thermal-isomerization^{3,4} of **17a** in refluxing EtOH and purification by preparative HPLC furnished



Scheme 2. a) 4-Phenyl-3*H*-1,2,4-triazole-3,5(4*H*)-dione; b) O₃/1% Py-CH₂Cl₂, then Me₂S; c) **9a** or **9b**, *n*-BuLi/THF; d) Na-Hg/MeOH (Na₂HPO₄); e) PPTS/EtOH; f) LiAlH₄/THF; g) *hν*; h) reflux/EtOH.

1 α ,25-dihydroxyvitamin D₂ (**1a**) in 22% yield from **16a**. The physical and spectral data of **1a** were in accord with those reported earlier.^{8,10}

Similarly, (24*R*,22*E*)-5,7,22-ergostatriene-1 α ,3 β ,25-triol (**16b**) was prepared from the aldehyde (**12**) and the sulfone (**9b**) in place of **9a** in four steps in 15% yield from **12**. Irradiation of **16b** and purification by preparative HPLC gave the previtamin D (**17b**), which was thermally isomerized to afford the crystalline (24*R*)-1 α ,25-dihydroxyvitamin D₂ (**1b**) in 12% yield from **16b** after purification by preparative HPLC.

Since (22*E*)-5,7,22-ergostatriene-1 α ,3 β ,25-triol is obtainable readily from (22*E*)-5,7,22-ergostatriene-1 α ,3 β -diyl diacetate (**10**), the present study provides an efficient method for the preparation of 1 α ,25-dihydroxyvitamin D₂. The synthetic method described here will be applicable to other 1 α -hydroxylated vitamin D₂ or D₃ derivatives.

Experimental

All the melting points and boiling points are uncorrected. IR spectra were measured on a Jasco IR-810 spectrometer. ¹H NMR spectra were recorded with TMS as an internal standard and CDCl₃ as a solvent at 200 MHz on a JEOL JNM-FX 200 spectrometer unless otherwise stated. Optical rotations were measured with CHCl₃ as a solvent on a Jasco DIP-4 polarimeter or a Jasco DIP-370 polarimeter unless otherwise stated. Mass spectra were recorded on a Hitachi M-80 spectrometer at 70 eV. UV spectra were measured on a Hitachi 320 spectrometer. Merck Kieselgel 60 (Art 7734, 70–230 mesh) or Merck Kieselgel 60 (Art 9385, 230–400 mesh) were used for SiO₂ column chromatography. TLC analyses were performed on a Merck Kieselgel 60 F-254 (Art 5715, 0.25 mm).

(S)-2,3-Dimethyl-1,3-butanediol (5a). A solution of methyl (S)-3-hydroxy-2-methylpropionate (**2a**) (8.09 g, 68.6 mmol; Sigma Chemical Co.), dihydropyran (8.63 g, 0.10 mol), and *p*-TsOH·H₂O (0.10 g) in dry ether (50 ml) was stirred for 1 h. The mixture was washed with sat. NaHCO₃ solution and brine, dried (MgSO₄), and concentrated in vacuo to give 13.8 g of crude **3a**. Its IR spectrum was identical with that reported previously.¹³ This was employed in the next step without further purification.

A Grignard reagent was prepared from methyl iodide (29.2 g, 0.21 mol) and magnesium (5.00 g, 0.21 mol) in dry ether (30 ml). To this Grignard solution, a solution of crude **3a** (13.8 g) in dry ether (30 ml) was added dropwise for 1 h at a rate sufficient to maintain a gentle reflux. The mixture was stirred for 2 h at reflux temperature. Then to the ice-cooled reaction mixture was carefully added dropwise a cold sat. NH₄Cl solution. The ether layer was separated and the aq. layer was extracted with ether. The combined ether solution was washed with brine, dried (MgSO₄), and concentrated in vacuo to give 13.5 g of crude **4a**: IR (film) 3460, 1460, 1390, 1205, 1180, 1125, 1080, 1060, 980 cm⁻¹. This was employed in the next step without further purification.

A solution of crude **4a** (13.5 g) and *p*-TsOH·H₂O (0.65 g, 3.4 mmol) in MeOH (150 ml) was stirred for 1 h at room temperature. The mixture was neutralized with K₂CO₃ and filtered through Celite. After removal of MeOH in vacuo

from the filtrate, the residue was dissolved in ether. The ether solution was dried (MgSO₄), and concentrated in vacuo. The residue was distilled to give 6.28 g (84% from **2a**) of **5a**: bp 83–85 °C/0.22 mmHg (1 mmHg≈133.322 Pa); *n*_D²⁵ 1.4439; [α]_D²⁵+1.7° (*c* 5.12)[lit.¹²] [α]_D²⁵-2.5° (0.18%, CHCl₃); IR (film) 3350, 1470, 1385, 1370, 1175, 1160, 1030 cm⁻¹; ¹H NMR δ =0.84 (3H, d, *J*=7.1 Hz), 1.18 (3H, s), 1.25 (3H, s), 1.81 (3H, m), 3.70 (1H, m), 3.91 (1H, s), 4.17 (1H, t, *J*=4.6 Hz). Found: *m/z* 118.1000. Calcd for C₆H₁₄O₂: *M*, 118.0994.

(S)-3-Hydroxy-2,3-dimethylbutyl *p*-Toluenesulfonate (6a). To a stirred and ice-cooled solution of **5a** (6.00 g, 50.8 mmol) in dry pyridine (24 ml) was added *p*-toluenesulfonyl chloride (11.64 g, 61.1 mmol) and the mixture was stirred for 2 h at that temperature. The mixture was poured into ice water and extracted with ether. The ether solution was washed with water, sat. CuSO₄ solution, sat. NaHCO₃ solution and brine, dried (MgSO₄), and concentrated in vacuo to give 13.5 g of crude **6a**: IR (film) 3450, 1600, 1500, 1470, 1360, 1190, 1175, 1100, 965 cm⁻¹; ¹H NMR δ =0.96 (3H, d, *J*=7.1 Hz), 1.12 (3H, s), 1.19 (3H, s), 1.54 (1H, s), 1.80 (1H, m), 2.45 (3H, s), 3.92 (1H, dd, *J*=9.5 and 9.8 Hz), 4.23 (1H, dd, *J*=9.5 and 4.4 Hz), 7.35 (2H, d, *J*=8.3 Hz), 7.80 (2H, d, *J*=8.3 Hz). This was employed in the next step without further purification.

(R)-2,3-Dimethyl-4-phenylthio-2-butanol (7a). To a stirred solution of potassium *t*-butoxide (5.89 g, 53.4 mmol) and benzenethiol (5.87 g, 53.4 mmol) in dry DMF (60 ml) was added crude **6a** (13.5 g) and the mixture was stirred for 4 h at room temperature under N₂. The mixture was poured into water and extracted with benzene. The benzene solution was washed with water and brine, dried (MgSO₄), and concentrated in vacuo. The residue was chromatographed over SiO₂ (100 g) eluting with hexane-EtOAc (9:1) to give 10.13 g of **7a**: IR (film) 3420, 3060, 1590, 1485, 1440, 1375, 1140, 1095, 1030 cm⁻¹; ¹H NMR δ =0.96 (3H, d, *J*=6.8 Hz), 1.18 (3H, s), 1.23 (3H, s), 1.54 (1H, s), 1.80 (1H, m), 2.55 (1H, dd, *J*=10.1 and 12.7 Hz), 3.40 (1H, dd, *J*=10.1 and 2.9 Hz), 7.15–7.48 (5H, m). This was employed in the next step without further purification.

(R)-2,3-Dimethyl-4-phenylsulfonyl-2-butanol (8a). WO₃ (55 mg) in water (18 ml) was dissolved by adding 50% NaOH solution to pH 11, the solution was then adjusted to pH 5.6 by adding AcOH. To this solution was added **7a** (10.13 g) in EtOH (10 ml) and then 30% H₂O₂ (3.4 ml). The mixture was stirred for 10 min at 60 °C. To the mixture was added 30% H₂O₂ (3.4 ml) and the mixture was stirred for a further 30 min at 75 °C. After cooling, Na₂S₂O₃ was added to the reaction mixture. The mixture was next extracted with benzene. The benzene solution was washed with water and brine, dried (MgSO₄), and concentrated in vacuo. The residue was chromatographed over SiO₂ (200 g) eluting with hexane-EtOAc (9:1–4:1) to give 11.32 g (92% from **5a**) of **8a**, which crystallized on standing. Recrystallization from ether gave **8a** as prisms: mp 68.4–69.1 °C; [α]_D²⁵-33.7° (*c* 1.26) [lit.¹²] [α]_D²²-22.4° (0.6%, CHCl₃); IR (KBr) 3500, 3070, 1585, 1450, 1370, 1300, 1155, 1140, 1110, 1085 cm⁻¹; ¹H NMR δ =1.03 (3H, s), 1.12 (3H, d, *J*=6.8 Hz), 1.22 (3H, s), 1.88 (1H, s), 2.15 (1H, m), 2.82 (1H, dd, *J*=13.9 and 9.3 Hz), 3.60 (1H, dd, *J*=13.9 and 2 Hz), 7.53–7.95 (5H, m). Found: C, 59.49; H, 7.48; S, 13.25%. Calcd for C₁₂H₁₈O₃S: C, 59.48; H, 7.49; S, 13.23%.

(3R)-2,3-Dimethyl-4-phenylsulfonyl-2-butanol THP Ether

(9a). A solution of **8a** (5.31 g, 21.9 mmol), dihydropyran (2.76 g, 32.9 mmol) and PPTS (0.55 g, 2.2 mmol) in dry CH₂Cl₂ (60 ml) was stirred for 4 h at room temperature. The mixture was washed with water and brine, dried (MgSO₄), and concentrated in vacuo. The residue was chromatographed over SiO₂ (150 g) eluting with hexane-EtOAc (4:1) to give 6.58 g (92%) of **9a**: IR (film) 3060, 1585, 1450, 1395, 1305, 1200, 1150, 1110, 1090, 1085, 1025 cm⁻¹; ¹H NMR δ =1.04 and 1.06 (3H, pair of s), 1.13 (3H, m), 1.18 and 1.19 (3H, pair of s), 1.3–1.8 (6H, m), 2.19 (1H, m), 2.88 (1H, m), 3.42 (1H, m), 3.65 (1H, m), 3.82 (1H, m), 4.73 (1H, m), 7.51–7.94 (5H, m).

(*R*)-2,3-Dimethyl-1,3-butanediol (**5b**). In the same manner as described for **5a**, methyl (*R*)-3-hydroxy-2-methylpropionate (**2b**) (9.28 g, 78.6 mmol; Sigma Chemical Co.) was converted in three steps to 7.61 g (82%) of **5b**: bp 83–84°C/0.25 mmHg; n_D^{25} 1.4437; $[\alpha]_D^{25}$ –1.6° (c 5.29). Its IR and ¹H NMR spectra were identical with those of **5a**.

(*S*)-2,3-Dimethyl-4-phenylsulfonyl-2-butanol (**8b**). In the same manner as described for **8a**, **5b** (6.58 g, 55.8 mmol) was converted in three steps to 12.10 g (90%) of **8b**: mp 68.2–69.0°C (from ether, prisms); $[\alpha]_D^{25}$ +34.1° (c 1.09) [lit.⁹ a thick, colorless oil; $[\alpha]_D^{25}$ +27.9° (c 1.3, CHCl₃)]. Its IR and ¹H NMR spectra were identical with those of **8a**. Found: C, 59.35; H, 7.48; S, 13.29%. Calcd for C₁₂H₁₈O₃S: C, 59.48; H, 7.49; S, 13.23%.

(3*S*)-2,3-Dimethyl-4-phenylsulfonyl-2-butanol THP Ether (**9b**). In the same manner as described for **9a**, **8b** (6.23 g, 25.7 mmol) was converted to 7.89 g (94%) of **9b**. Its IR and ¹H NMR spectra were identical with those of **9a**.

(22*E*)-5 α ,8 α -(4-Phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)-6,22-ergostadiene-1 α ,3 β -diyl Diacetate (**11**). To a stirred solution of (22*E*)-5,7,22-ergostatriene-1 α ,3 β -diyl diacetate (**10**) (5.62 g, 11.3 mmol) in CHCl₃ (70 ml) was added dropwise a solution of 4-phenyl-3*H*-1,2,4-triazole-3,5(4*H*)-dione (PTAD) (2.26 g, 13 mmol) in acetone (40 ml) at room temperature until a faint pink coloration persisted, and the mixture was concentrated in vacuo. The residue was chromatographed over SiO₂ (80 g) eluting with hexane-EtOAc (2:1) to give 6.61 g (87%) of **11** as a foam: $[\alpha]_D^{25}$ –139° (c 1.09); IR (KBr) 1750, 1700, 1600, 1505, 1395, 1240, 1030 cm⁻¹; ¹H NMR δ =0.79 and 0.82 (6H, each d, J =3.7 Hz, 26-H₃ and 27-H₃), 0.84 (3H, s, 18-H₃), 0.89 (3H, d, J =6.8 Hz, 28-H₃), 1.02 (3H, d, J =6.6 Hz, 21-H₃), 1.06 (3H, s, 19-H₃), 2.01 (3H, s, Ac), 2.03 (3H, s, Ac), 3.25 (1H, dd, J =13.7 and 5.6 Hz, 9-H), 5.11 (1H, m, 1-H), 5.20 (2H, m, 22-H and 23-H), 5.89 (1H, m, 3-H), 6.33 and 6.45 (2H, ABq, J =8.3 Hz, 6-H and 7-H), 7.24–7.51 (5H, m, Ph); MS m/z (rel intensity) 671(M⁺; 0.3), 496(0.4), 436(8), 376(100), 251(28), 209(23), 155(34).

22-Oxo-5 α ,8 α -(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)-23,24-dinor-6-chole-1 α ,3 β -diyl Diacetate (**12**). Ozone (flow rate 0.07 mmol min⁻¹) was bubbled into a solution of **11** (10.00 g, 14.9 mmol) in 1% pyridine-CH₂Cl₂ (400 ml) with stirring for 4.5 h at –65°C. After the excess ozone was driven out by bubbling Ar, dimethyl sulfide (20 ml) was added dropwise to the mixture at –65°C, and the mixture was stirred for 1 h at –65°C. After the cooling bath was removed, stirring was continued for a further 1 h. The mixture was washed with 2% HCl and brine, dried (MgSO₄), and concentrated in vacuo. The residue was chromatographed over SiO₂ (130 g) eluting with hexane-EtOAc (1:1) to give 5.99 g of **12**. This was recrystallized from benzene to give 4.40 g (49%) of **12** as needles: mp 191–193°C;

$[\alpha]_D^{25}$ –131° (c 1.06); IR (KBr) 2720, 1740, 1685, 1605, 1505, 1405, 1370, 1250, 1230, 1035 cm⁻¹; ¹H NMR δ =0.87 (3H, s, 18-H₃), 1.07 (3H, s, 19-H₃), 1.14 (3H, d, J =6.8 Hz, 21-H₃), 2.01 (3H, s, Ac), 2.04 (3H, s, Ac), 3.26 (1H, dd, J =14.2 and 5.4 Hz, 9-H), 5.12 (1H, m, 1-H), 5.88 (1H, m, 3-H), 6.36 and 6.44 (2H, ABq, J =8.3 Hz, 6-H and 7-H), 7.26–7.51 (5H, m, Ph), 9.55 (1H, d, J =3.4 Hz, 22-H); MS m/z (rel intensity) 603(M⁺; 0.3), 428(0.3), 368(11), 308(100), 235(20), 177(20), 141(57). Found: C, 67.57; H, 6.84; N, 6.99%. Calcd for C₃₄H₄₁N₃O₇: C, 67.64; H, 6.84; N, 6.96%.

(22*E*)-5 α ,8 α -(4-Phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)-25-tetrahydropyranyloxy-6,22-ergostadiene-1 α , 3 β -diol (**14a**). Butyllithium (1.5 moldm⁻³ in hexane, 3.5 ml, 5.2 mmol) was added to a stirred solution of **9a** (1.70 g, 5.2 mmol) in dry THF (60 ml) at –60––70°C under Ar. After stirring for 30 min, a solution of **12** (2.40 g, 4.0 mmol) in dry THF (25 ml) was added and the mixture was stirred for 30 min at –60––70°C. Sat. NH₄Cl solution (1 ml) was added dropwise to the mixture at that temperature, and the mixture was allowed to rise to room temperature. The mixture was poured into sat. NH₄Cl solution and extracted with EtOAc. The EtOAc solution was washed with brine, dried (MgSO₄), and concentrated in vacuo to give crude **13a**. This was employed in the next step without further purification.

To a solution of crude **13a** in MeOH saturated with Na₂HPO₄ (330 ml) sodium amalgam (5%, 18.3 g) was added and the mixture was stirred for 15 h at 0°C, followed by a further 3 h at room temperature. The supernatant was concentrated in vacuo, and the residue was poured into water and extracted with EtOAc. The EtOAc solution was washed with brine, dried (MgSO₄), and concentrated in vacuo. The residue was chromatographed over SiO₂ (65 g) eluting with hexane-EtOAc (1:4) to give 0.87 g (32% from **12**) of **14a** as a crystalline material: IR (KBr) 3420, 1745, 1685, 1600, 1505, 1405, 1315, 1130, 1025, 980 cm⁻¹; ¹H NMR δ =3.48 (1H, m, 6'-H), 3.69 (1H, m, 1-H), 3.95 (1H, m, 6'-H), 4.78 (1H, m, 2'-H), 4.85 (1H, m, 3-H), 5.15–5.42 (2H, m, 22-H and 23-H), 6.18 and 6.34 (2H, ABq, J =8.3 Hz, 6-H and 7-H), 7.2–7.4 (5H, m, Ph); MS m/z (rel intensity) 512 (M⁺–PTAD; 0.3), 428(3), 410(22), 324(3), 251(5), 177(22), 119(28), 85(100), 59(94). This was employed in the next step without further purification.

(22*E*)-5,7,22-Ergostatriene-1 α ,3 β ,25-triol (**16a**). A solution of **14a** (0.84 g, 1.2 mmol) and PPTS (15 mg, 0.06 mmol) in 95% EtOH (6 ml) was stirred for 1 h at 50°C. After removal of EtOH in vacuo from the mixture, the residue was extracted with EtOAc. The EtOAc solution was washed with brine, dried (MgSO₄), and concentrated in vacuo to give crude **15a**. This was employed in the next step without further purification. An analytical sample was prepared by recrystallization from ether-EtOH to give **15a** as needles: mp 209–212°C; $[\alpha]_D^{25}$ –86.4° (c 0.22); IR (KBr) 3530, 3470, 1745, 1680, 1505, 1415, 1150, 1035 cm⁻¹; ¹H NMR δ =0.84 (3H, s, 18-H₃), 0.93 (3H, s, 19-H₃), 0.98 (3H, d, J =7.1 Hz, 28-H₃), 1.05 (3H, d, J =6.6 Hz, 21-H₃), 1.13 and 1.16 (6H, each s, 26-H₃ and 27-H₃), 1.21 (t, J =7.1 Hz, Et₂O), 3.15 (1H, dd, J =14 and 7.1 Hz, 9-H), 3.48 (q, J =7.1 Hz, Et₂O), 3.85 (1H, m, 1-H), 4.90 (1H, m, 3-H), 6.26 and 6.41 (2H, ABq, J =8.3 Hz, 6-H and 7-H), 7.30–7.45 (5H, m, Ph); MS m/z (rel intensity) 428(M⁺–PTAD; 18), 350(15), 324(25), 251(15), 177(90), 119(100). Found: C, 71.06; H, 8.28; N, 6.81%. Calcd for C₃₆H₄₉N₃O₅·1/4 Et₂O: C, 71.41; H, 8.34; N, 6.75%.

A mixture of crude **15a** and LiAlH₄ (0.73 g) in dry THF (80 ml) was stirred for 1.5 h at reflux temperature. The excess LiAlH₄ was destroyed by the successive addition of water (0.7 ml), 10% NaOH solution (0.7 ml), water (2.1 ml) to the stirred and ice-cooled mixture. The mixture was stirred for a further 30 min at room temperature, dried (MgSO₄), and filtered through Celite. The filtrate was concentrated in vacuo to give crude crystalline **16a**. This was recrystallized from EtOH to give 0.28 g (54% from **14a**) of **16a** as needles: mp 222–224 °C; $[\alpha]_D^{25} -55^\circ$ (*c* 0.12, MeOH); IR (KBr) 3520, 3350, 1655, 1610, 1465, 1370, 1135, 1070, 975 cm⁻¹; ¹H NMR $\delta = 0.64$ (3H, s, 18-H₃), 0.95 (3H, s, 19-H₃), 1.00 (3H, d, *J* = 7.1 Hz, 28-H₃), 1.05 (3H, d, *J* = 6.8 Hz, 21-H₃), 1.13 and 1.17 (6H, each s, 26-H₃ and 27-H₃), 3.77 (1H, m, 1-H), 4.04 (1H, m, 3-H), 5.35 (3H, m, 7-H, 22-H and 23-H), 5.73 (1H, m, 6-H); MS *m/z* (rel intensity) 428 (*M*⁺; 4), 353 (2), 312 (2), 251 (5), 225 (5), 145 (8), 81 (15), 59 (100); UV (EtOH) 282 nm (ϵ 11900). Found: C, 77.97; H, 10.40%. Calcd for C₂₈H₄₄O₃: C, 78.48; H, 10.35%.

1 α ,25-Dihydroxyvitamin D₂ (1a). A solution of **16a** (100 mg, 0.23 mmol) in ether-THF (19:1, 1000 ml) was irradiated for 3 min under Ar at water-cooled temperature with a high-pressure mercury lamp (Ushio, UM-452) using 1.5% KNO₃ solution as a filter. The mixture was next concentrated in vacuo. A solution of the residue containing the previtamin D (**17a**) in EtOH (30 ml) was stirred for 1 h at reflux temperature under Ar. The mixture was concentrated in vacuo. The residue was chromatographed on HPLC (Merck, LiChrosorb[®] Si60 (7 μ m), 25×250 mm) eluting with 4% MeOH-CH₂Cl₂ (8.0 ml min⁻¹) to give 22 mg (22% from **16a**) of crystalline **1a**. This was recrystallized from hexane-ether to give **1a** as needles: mp 168–170 °C; $[\alpha]_D^{25} +48^\circ$ (*c* 0.07, EtOH) [lit.¹⁰ mp 169–170 °C; $[\alpha]_D^{25} +47.2^\circ$ (*c* 0.2, EtOH)]; IR (KBr) 3400, 1640, 1460, 1380, 1370, 1350, 1300, 1265, 1220, 1140, 1055, 975 cm⁻¹; ¹H NMR $\delta = 0.56$ (3H, s, 18-H₃), 1.00 (3H, d, *J* = 6.8 Hz, 28-H₃), 1.04 (3H, d, *J* = 6.8 Hz, 21-H₃), 1.13 and 1.17 (6H, each s, 26-H₃ and 27-H₃), 4.23 (1H, m, 3-H), 4.42 (1H, m, 1-H), 5.00 (1H, narrow m, 19-H), 5.32 (3H, m, 19-H, 22-H and 23-H), 6.01 (1H, d, *J* = 10.6 Hz, 7-H), 6.38 (1H, d, *J* = 10.6 Hz, 6-H); MS *m/z* (rel intensity) 428 (*M*⁺; 5), 410 (9), 392 (12), 352 (6), 269 (10), 197 (15), 152 (23), 134 (100); UV (EtOH) 265 nm (ϵ 16400). Found: *m/z* 428.3271. Calcd for C₂₈H₄₄O₃: *M*, 428.3292.

(24*R*,22*E*)-5 α ,8 α -(4-Phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)-25-tetrahydropyranyloxy-6,22-ergostadiene-1 α ,3 β -diol (14b). In the same manner as described for **14a**, **12** (1.50 g, 2.5 mmol) and **9b** (1.62 g, 5.0 mmol) was converted in two steps to 0.46 g (27%) of **14b**: IR (KBr) 3430, 1750, 1690, 1605, 1505, 1410, 1310, 1135, 1030, 985 cm⁻¹; ¹H NMR $\delta = 3.50$ (1H, m, 6'-H), 3.71 (1H, m, 1-H), 3.90 (1H, m, 6'-H), 4.75 (1H, m, 2'-H), 4.85 (1H, m, 3-H), 5.15–5.40 (2H, m, 22-H and 23-H), 6.19 and 6.35 (2H, ABq, *J* = 8.3 Hz, 6-H and 7-H), 7.2–7.4 (5H, m, Ph); MS *m/z* (rel intensity) 428 (*M*⁺–PTAD–DHP; 10), 410 (7), 350 (12), 177 (40), 119 (100).

(24*R*,22*E*)-5 α ,8 α -(4-Phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)-6,22-ergostadiene-1 α ,3 β ,25-triol (15b). This was prepared in the same manner as described for **15a**, and recrystallization from ether-EtOH gave an analytical sample as needles: mp 212–215 °C; $[\alpha]_D^{25} -95.6^\circ$ (*c* 0.25); IR (KBr) 3530, 3450, 1745, 1680, 1505, 1420, 1155, 1035 cm⁻¹; ¹H NMR $\delta = 0.83$ (3H, s, 18-H₃), 0.92 (3H, s, 19-H₃), 0.98 (3H, d, *J* = 7.1 Hz, 28-H₃), 1.04 (3H, d, *J* = 6.4 Hz, 21-H₃), 1.12 and 1.15 (6H, each s, 26-H₃ and 27-H₃), 1.21 (t, *J* = 7.1 Hz, Et₂O), 3.14 (1H,

dd, *J* = 13.7 and 4.4 Hz, 9-H), 3.48 (q, *J* = 7.1 Hz, Et₂O), 3.83 (1H, m, 1-H), 4.90 (1H, m, 3-H), 5.32 (2H, m, 22-H and 23-H), 6.25 and 6.40 (2H, ABq, *J* = 8.1 Hz, 6-H and 7-H), 7.30–7.45 (5H, m, Ph); MS *m/z* (rel intensity) 428 (*M*⁺–PTAD; 22), 350 (16), 324 (48), 251 (20), 177 (75), 119 (100). Found: C, 70.63; H, 8.34; N, 6.62%. Calcd for C₃₆H₄₉N₃O₅·1/4 Et₂O: C, 71.41; H, 8.34; N, 6.75%.

(24*R*,22*E*)-5,7,22-Ergostatriene-1 α ,3 β ,25-triol (16b). In the same manner as described for **16a**, **14b** (0.87 g, 1.3 mmol) was converted in two steps to 0.31 g (57%) of **16b**: mp 214–217 °C (from EtOH, needles); $[\alpha]_D^{25} -16.2^\circ$ (*c* 0.14, MeOH); IR (KBr) 3510, 3360, 1660, 1610, 1465, 1385, 1145, 1075, 970 cm⁻¹; ¹H NMR $\delta = 0.65$ (3H, s, 18-H₃), 0.95 (3H, s, 19-H₃), 0.99 (3H, d, *J* = 6.8 Hz, 28-H₃), 1.05 (3H, d, *J* = 6.8 Hz, 21-H₃), 1.13 and 1.17 (6H, each s, 26-H₃ and 27-H₃), 3.77 (1H, m, 1-H), 4.08 (1H, m, 3-H), 5.35 (3H, m, 7-H, 22-H and 23-H), 5.74 (1H, m, 6-H); MS *m/z* (rel intensity) 428 (*M*⁺; 42), 251 (60), 225 (62), 157 (100), 145 (80); UV (EtOH) 282 nm (ϵ 11700). Found: C, 78.24; H, 10.37%. Calcd for C₂₈H₄₄O₃: C, 78.48; H, 10.35%.

(24*R*)-1 α ,25-Dihydroxyvitamin D₂ (1b). A solution of **16b** (100 mg, 0.23 mmol) in ether-THF (19:1, 1000 ml) was irradiated for 3 min under Ar at water-cooled temperature with a high pressure mercury lamp (Ushio, UM-452) using 1.5% KNO₃ solution as a filter. The mixture was next concentrated in vacuo. The residue was chromatographed over HPLC (Merck, LiChrosorb[®] Si60 (7 μ m), 25×250 mm) eluting with 5% MeOH-CH₂Cl₂ (8.0 ml min⁻¹) to give 28 mg (28%) of the previtamin D (**17b**): ¹H NMR $\delta = 0.72$ (3H, s, 18-H₃), 0.99 (3H, d, *J* = 6.8 Hz, 28-H₃), 1.05 (3H, d, *J* = 6.6 Hz, 21-H₃), 1.13 and 1.17 (6H, each s, 26-H₃ and 27-H₃), 1.76 (3H, s, 19-H₃), 4.05 (1H, m, 3-H), 4.19 (1H, m, 1-H), 5.31 (2H, m, 22-H and 23-H), 5.51 (1H, m, 9-H), 5.76 and 5.92 (2H, ABq, *J* = 12.9 Hz, 6-H and 7-H).

A solution of **17b** (28 mg) in EtOH (15 ml) was stirred for 1 h at reflux temperature. The mixture was concentrated in vacuo. The residue was chromatographed on HPLC (Merck, LiChrosorb[®] Si60 (7 μ m), 25×250 mm) eluting with 5% MeOH-CH₂Cl₂ (7.0 ml min⁻¹) to give 11.8 mg (42%: 12% from **16b**) of **1b**. This was recrystallized from hexane-CH₂Cl₂ to give **1b** as rods: mp 150–152 °C [lit.⁹] a colorless oil; $[\alpha]_D^{25} +74^\circ$ (*c* 0.16, EtOH); ¹H NMR $\delta = 0.56$ (3H, s, 18-H₃), 0.99 (3H, d, *J* = 6.8 Hz, 28-H₃), 1.03 (3H, d, *J* = 6.6 Hz, 21-H₃), 1.12 and 1.17 (6H, each s, 26-H₃ and 27-H₃), 4.22 (1H, m, 3-H), 4.42 (1H, m, 1-H), 4.99 (1H, narrow m, 19-H), 5.32 (3H, m, 19-H, 22-H and 23-H), 6.01 (1H, d, *J* = 11.2 Hz, 7-H), 6.37 (1H, d, *J* = 11.2 Hz, 6-H); MS *m/z* (rel intensity) 428 (*M*⁺; 6), 410 (7), 392 (10), 352 (5), 334 (16), 269 (9), 251 (10), 134 (100), 105 (46); UV (EtOH) 265 nm (ϵ 16900).

References

- 1) T. Suda, H. F. DeLuca, H. K. Schnoes, and J. W. Blunt, *Biochemistry*, **8**, 3515 (1969).
- 2) G. Jones, H. K. Schnoes, and H. F. DeLuca, *Biochemistry*, **14**, 1250 (1975).
- 3) H.-Y. Lam, H. K. Schnoes, and H. F. DeLuca, *Science*, **186**, 1038 (1974).
- 4) H.-Y. Lam, H. K. Schnoes, and H. F. DeLuca, *Steroids*, **30**, 2181 (1977).
- 5) M. F. Holich, E. J. Semmler, H. K. Schnoes, and H. F. DeLuca, *Science*, **180**, 190 (1973).
- 6) D. H. R. Barton, R. H. Hesse, M. M. Pechet, and E.

- Rizzardo, *J. Am. Chem. Soc.*, **95**, 2748 (1973).
- 7) G. Sjöden, C. Smith, U. Lindgren, and H. F. DeLuca, *Pro. Soc. Exp. Biol. Med.*, **178**, 432 (1985).
- 8) R. R. Sicinski, Y. Tanaka, H. K. Schnoes, and H. F. DeLuca, *Bioorg. Chem.*, **13**, 158 (1985).
- 9) A. Kutner, K. L. Perlman, R. R. Sicinski, M. E. Phelps, H. K. Schnoes, and H. F. DeLuca, *Tetrahedron Lett.*, **28**, 6129 (1987); A. Kutner, K. L. Perlman, A. Lago, R. R. Sicinski, H. K. Schnoes, and H. F. DeLuca, *J. Org. Chem.*, **53**, 3450 (1988).
- 10) E. G. Baggiolini, J. A. Iacobelli, B. M. Hennessy, A. D. Batcho, J. F. Sereno, and M. R. Uskoković, *J. Org. Chem.*, **51**, 3098 (1986).
- 11) Y. Tachibana, *Bull. Chem. Soc. Jpn.*, **61**, 3915 (1988).
- 12) S. Yamada, M. Shiraishi, M. Ohmori, and H. Takayama, *Tetrahedron Lett.*, **25**, 3347 (1984).
- 13) K. Mori, *Tetrahedron*, **39**, 3107 (1983).
- 14) D. H. R. Barton, T. Shioiri, and D. A. Widdowson, *J. Chem. Soc. C*, **1971**, 1968.
- 15) D. S. Morris, D. H. Williams, and A. F. Norris, *J. Org. Chem.*, **46**, 3422 (1981).
- 16) P. J. Kocienski, B. Lythgoe, and S. Ruston, *J. Chem. Soc., Perkin Trans. 1*, **1978**, 829.
- 17) P. J. Kocienski, B. Lythgoe, and D. A. Roberts, *J. Chem. Soc., Perkin Trans. 1*, **1978**, 843.
- 18) P. J. Kocienski, B. Lythgoe, S. Ruston, and I. Waterhouse, *J. Chem. Soc., Perkin Trans. 1*, **1980**, 1045.
- 19) The (*E*)-geometry was finally confirmed by the single-crystal X-ray analysis of **16a**. This will be reported elsewhere.
-